- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02468245
Does a Nursing Intervention Improve Adherence to Oral Chemotherapies in the Outpatient Cancer Treatment Setting?
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The purpose of this study is to investigate which nursing intervention will help to improve adherence in adult patients who are receiving oral chemotherapy. This study will identify the barriers to adherence, interventions that will increase patients' adherence, and the role of nursing in promoting oral chemotherapy adherence. Oral chemotherapy adherence is important in the setting of cancer care as many new chemotherapy medications being approved for use are oral chemotherapies. Nursing responsibility in this study is to help promote interventions that would improve adherence. The literature shows that the best intervention to promote adherence to oral chemotherapy is education that patients receive prior to them starting their treatment. The interventions such as the MEMS system, AVR, and the generic diary were studied and found to be somewhat effective in improving adherence, but not reliable. The literature supports the use of individualized and personalized education for patients. The education should be in terms that they can understand and absorb, and it should be information that they need related to their treatment.
Oral chemotherapy has emerged as the growing treatment of choice in the cancer treatment specialty; accounting for a quarter of the 400 anticancer medications currently under development (Simchowitz et al., 2010). There are now more than 20 oral antineoplastic agents approved for use in the United States alone; and dozens more under development (Ruddy, Mayer, & Partridge, 2009). Chemotherapy treatments are moving in the direction of conveniences for patients. Oral chemotherapies can be given to patients to take home and be administered in the convenience of their homes. This process works for some patients, but not all.
One of the biggest issues that health care providers find with oral chemotherapy is the non-adherence with the regimens. Without nursing education and follow up interventions, adherence is even more difficult to obtain. Although some patients want to experience having the same care and intervention as a patient receiving intravenous chemotherapy, the mindset of receiving oral chemotherapy is that it is just a pill and not taken seriously by some patients. In a study conducted at Dana Farber, most patients would prefer oral chemotherapy to intravenous (IV) chemotherapy for its convenience, ease of use, and painless administration (Simchowitz et al., 2010). Although most patients realize the importance of taking their medication and adhering to the regimen, they are still non-adherent and suffer unneeded side effects due to that non-adherence. Not to mention that they do not get the full therapeutic effect of the oral chemotherapy regimen.
The standard process for treatment with oral chemotherapy agents start with the providers request for the agent via prescription. Once patient has received approval and has the drug available, the patient will call the cancer center to set up a formal educational appointment with an oncology certified chemotherapy nurse (OCN). The OCN meets with the patient to review potential side effects, how to manage those side effects, and how to properly take the oral chemotherapy. It will be at this education appointment that, the patient will be approached for interest in the study.
Subjects will be identified as any patient that has an oral chemotherapy prescribed that meets the inclusion criteria (please see inclusion/exclusion criteria list later in this document). If the patient expresses interest informed consent process will begin.Once patient has given informed consent, the OCN will confirm eligibility. Once consented and eligibility verified, they will be randomized to either the control group (no intervention, standard of care [SOC]) or to the study group (the intervention group). The initial sample size is 60. All eligible patients' prescribed oral chemotherapy will be approached until sample size of 60 participants has been reached. An interim analysis will be completed after 60 patients have completed the study to assess adequacy of the sample size.
If randomized to the study arm, the OCN will follow-up with that patient at week one, two, three via phone,. At week four, follow-up will occur at the patients routinely scheduled medical oncology visit. For the control group, data will be collected at initial education visit and again at the 4 week physician visit. At the initial education visit both the study group and the control group will receive the standard chemotherapy education, and complete a QOL questionnaire. For the study group, at the initial education visit, a time for each phone call that is convenient for the patient will be scheduled. At each phone call, the OCN will get a pill count and discuss reasons for missed doses if applicable; grade any adverse events (AE's) experienced and interventions for those side effects; and answer any questions or concerns that they patient may be having.
The control group will not receive contact by the OCN at week 1, 2 and 3. At week four, both the control group and the study group will have a complete physical, pill count, QOL completion and document any AE experienced.
The quality of life (QOL) survey tool will be a questionnaire that is self-reported by the patient. This will be done at the initial education session and again at the four week follow up session, for both the control and the intervention group. The sample size will be 60 participants, 30 for the control group and 30 for the intervention group.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
New York
-
Cooperstown, New York, Forente stater, 13326
- Bassett Healthcare Network
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Must be >= 18 years of age
- Have a diagnosis of Cancer that will require an oral chemotherapy
- Be treated at Bassett Medical Center Cancer Center
- Must not be receiving radiation or infusional chemotherapy concomitantly with their oral chemotherapy
Exclusion Criteria:
- Being treated at satellite sites
- Receiving radiation and/or infusional chemotherapy concurrently with oral chemotherapy
- Due to impairment or other reasons, patient unable to provide consent or comply with survey.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Control Arm
This is a "usual care" group.
Patients in this arm will receive the standard pre-drug initiation training and 4 week clinic follow up visit.
|
The control group will receive the standard chemotherapy education and will return for the standard 4 week follow up clinic visit.
|
Eksperimentell: Intervention arm
Patients in this arm will also receive the standard pre-drug initiation training followed by telephone follow up by an oncology certified chemotherapy nurse (OCN) at week one, two, and three.
Patients will then have the standard 4 week follow up clinic visit.
|
For the study group, at the initial education visit, a time for each phone call that is convenient for the patient will be scheduled.
At each phone call, the OCN will get a pill count and discuss reasons for missed doses if applicable; grade any AE's experienced and interventions for those side effects; and answer any questions or concerns that they patient may be having.
Patients will then return for the standard 4 week clinic visit.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Oral chemotherapy compliance
Tidsramme: 4 weeks
|
A 4 week pill count will be completed on all participants to measure drug compliance.
|
4 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Kristina Loeffler, RN, Bassett Healthcare
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- 1096
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Antineoplastiske midler
-
Avid RadiopharmaceuticalsFullførtStrålingseksponering | Diagnostisk agent bivirkningForente stater
-
Boston Scientific CorporationAktiv, ikke rekrutterendeKinesiske pasienter behandlet med agent DCBTaiwan, Hong Kong, Singapore
-
Zonguldak Bulent Ecevit UniversityFullførtBryst sykdommer | Anestesi; Funksjonell | Volatil agent forbruk | Automatisk End-tidal kontrollert anestesiTyrkia
-
Laboratorios Sophia S.A de C.V.RekrutteringBakteriell konjunktivitt | Oftalmologisk agent toksisitetMexico
-
Assistance Publique - Hôpitaux de ParisUkjentInfeksjon | Viral, agent som årsak til sykdom klassifisert andre stederFrankrike
-
Asan Medical CenterSamsung Medical Center; Seoul National University Hospital; Korea University... og andre samarbeidspartnereFullførtKronisk viral hepatitt B uten Delta-agentKorea, Republikken
-
Asan Medical CenterFullførtKronisk viral hepatitt B uten Delta-agentKorea, Republikken
-
Asan Medical CenterSamsung Medical Center; Seoul National University Hospital; Korea University... og andre samarbeidspartnereFullførtKronisk viral hepatitt B uten Delta-agentKorea, Republikken
-
Kazakh Association of Internal Medicine SpecialistsHar ikke rekruttert ennåKronisk viral hepatitt B med Delta-AgentKasakhstan
Kliniske studier på usual care
-
Massachusetts General HospitalNational Institutes of Health (NIH); Samaritans of BostonHar ikke rekruttert ennåSelvmordstanker | Selvmord, forsøk | Selvmord
-
Albert Einstein College of MedicineColumbia University; University of Rochester; Rutgers UniversityFullførtPediatrisk fedme | Karies i tidlig barndomForente stater
-
VA Office of Research and DevelopmentFullførtPTSD | Posttraumatisk stresslidelseForente stater
-
Ohio State UniversityHar ikke rekruttert ennåPostpartum depresjon | Postpartum angst | Kardiometabolsk syndromForente stater
-
Johns Hopkins UniversityJohns Hopkins Alliance for a Healthier WorldAktiv, ikke rekrutterende
-
University of HawaiiIMPAQ International, LLC.FullførtSeksuelt overførbare infeksjoner | Tenåringsgraviditet
-
Massachusetts General HospitalNational Cancer Institute (NCI); Harvard Risk Management FoundationFullførtKreft | Brystkreft | Hode- og nakkekreft | Schizofreni | Lungekreft | Bipolar lidelse | Mage-tarmkreft | Alvorlig alvorlig depresjonForente stater
-
Yale UniversityNational Institute of Mental Health (NIMH)RekrutteringSelvmordstanker | Selvmord | SelvmordsforebyggingPakistan
-
University of AarhusKarolinska University Hospital; Aarhus University Hospital; National Research...FullførtSomatoforme lidelser | SomatiseringsforstyrrelseDanmark
-
The University of Texas Health Science Center,...Har ikke rekruttert ennåErnæring i høyrisikograviditetForente stater